LYMPHOMA, B-CELL

This early-phase study tests a new type of CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. The T-cells are modified to target cancer cells and include a safety switch that can be turned on to reduce severe side effects. The goa…

This early-phase study tests a new drug added to standard chemotherapy (R-GDP) for people with aggressive B-cell lymphoma that has returned or not responded to treatment. The main goal is to find the highest safe dose of the new combination. About 40 adults will take part, and re…

This study tests a new combination of drugs for people aged 75 and older with a type of blood cancer called DLBCL. The treatment pairs a targeted therapy (polatuzumab vedotin) with a lower-dose chemotherapy regimen (R-miniCHP) to see if it can keep the cancer from growing longer …

This early-phase trial tests a new treatment for people with B-cell cancers (like leukemia or lymphoma) that haven't improved with standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. Partici…

This early-phase trial tests a new treatment called FT819 for people with B-cell blood cancers (lymphoma, CLL, or B-ALL) that have not responded to standard therapies. The treatment uses specially engineered immune cells to target and attack cancer cells. The main goals are to fi…

This study offers ongoing access to ibrutinib for 297 people with certain blood cancers or graft-versus-host disease who completed earlier ibrutinib trials and still benefit from the drug but cannot get it commercially. Participants continue their current treatment while research…

This study tests an experimental drug called valemetostat tosylate in 141 people with B-cell lymphoma that has returned or stopped responding to standard treatments. The drug is taken alone and aims to shrink tumors. The study includes six different lymphoma types, including aggr…

This study tests a new oral drug called ARQ 531 (nemtabrutinib) in about 190 people with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to prior therapy. The goal is to find the safest dose and see if the drug can shrink tumors. Participants…

This study tests a new way to calculate the dose of melphalan chemotherapy for lymphoma patients getting a stem cell transplant. Instead of a standard dose based on height and weight, researchers use a model that considers how previous patients processed the drug, aiming for the …